作者
Yusuke Sakaguchi, Takayuki Hamano, Yoshitsugu Obi, Chikako Monden, Tatsufumi Oka, Satoshi Yamaguchi, Isao Matsui, Nobuhiro Hashimoto, Ayumi Matsumoto, Karin Shimada, Yoshitsugu Takabatake, Atsushi Takahashi, Jun-Ya Kaimori, Toshiki Moriyama, Ryohei Yamamoto, Masaru Horio, Koichi Yamamoto, Ken Sugimoto, Hiromi Rakugi, Yoshitaka Isaka
发表日期
2019/6/1
期刊
Journal of the American Society of Nephrology
卷号
30
期号
6
页码范围
1073-1085
出版商
LWW
简介
Background
Developing strategies for managing coronary artery calcification (CAC) in patients with CKD is an important clinical challenge. Experimental studies have demonstrated that magnesium inhibits vascular calcification, whereas the uremic toxin indoxyl sulfate aggravates it.
Methods
To assess the efficacy of magnesium oxide (MgO) and/or the oral carbon adsorbent AST-120 for slowing CAC progression in CKD, we conducted a 2-year, open-label, randomized, controlled trial, enrolling patients with stage 3− 4 CKD with risk factors for CAC (diabetes mellitus, history of cardiovascular disease, high LDL cholesterol, or smoking). Using a two-by-two factorial design, we randomly assigned patients to an MgO group or a control group, and to an AST-120 group or a control group. The primary outcome was percentage change in CAC score.
Results
We terminated the study prematurely after an interim analysis with …
学术搜索中的文章
Y Sakaguchi, T Hamano, Y Obi, C Monden, T Oka… - Journal of the American Society of Nephrology, 2019